Anal Cancer Market to Surpass US$ 1,242.9 Million by 2028

Global Anal Cancer Market, by Drug Type (Fluorouracil, Cisplatin, Carboplatin, and Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)), by Cancer Type (Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, and Basal Cell Carcinoma), by Treatment Type (Chemotherapy, Surgery, Radiation Therapy, and Immunotherapy), by Distribution Channel (Hospitals & Clinics, Research & Academic Institutes, Long-term Care Centers, and Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 810.4 million in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market and governments are focusing on carrying out research and development activities for developing novel therapeutics for treatment of anal cancer and this is expected to drive the global anal cancer market growth over the forecast period.

For instance, National Cancer Institute (NCI), U.S. is carrying out phase II clinical trial study to assess the effect of cetuximab used together with cisplatin, fluorouracil, and radiation therapy to treat immunocompromised patients suffering from stage I, II, or III anal cancer and this study is expected to be completed by May 2022.

Global Anal Cancer Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 231 million cases and 4.7 million deaths due to Coronavirus (COVID-19) were reported up till September 26, 2021, across the globe.

The COVID-19 pandemic has negatively affected several markets across the globe and is also expected to hamper the demand and supply in global anal cancer market, owing to lockdowns, halt of clinical trials related to cancer and lack of labour involved in manufacturing of drugs. For instance, according to an article published by the Nepal Journal of Epidemiology in September 2020, COVID-19 pandemic has raised many challenges in the field of clinical research such as implementation of strict guidelines which restrict physical interaction between the participants of a clinical trial study and the clinical trial personnel, thus leading to halt of clinical trials during the COVID-19 pandemic.

Browse 38 Market Data Tables and 28 Figures spread through 154 Pages and in-depth TOC on “Anal Cancer Market”- Global Forecast to 2028, by Drug Type (Fluorouracil, Cisplatin, Carboplatin, and Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)), by Cancer Type (Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, and Basal Cell Carcinoma), by Treatment Type (Chemotherapy, Surgery, Radiation Therapy, and Immunotherapy), by Distribution Channel (Hospitals & Clinics, Research & Academic Institutes, Long-term Care Centers, and Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the global anal cancer market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anal-cancer-market-4701

Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations and acquisitions, in order to strengthen their position in the market. For instance, in October 2017, MacroGenics, Inc., a U.S. based clinical-stage biopharmaceutical company and Incyte, a U.S. based biopharmaceutical company announced collaboration and license agreement for MGA012, an investigational monoclonal antibody drug manufactured by MacroGenics, Inc. for treatment of cancers such as anal cancer, Merkel cell carcinoma, and others.

Key Takeaways of the Global Anal Cancer Market:

• The global anal cancer market is expected to exhibit a CAGR of 6.3% over the forecast period, owing to rising incidence of anal cancer. For instance, according to the Cancer Research U.K., the incidence rate of anal cancer has increased by 41% in U.K with 15% increase in rate of anal cancer in males and 59% increase in females from 2015 to 2017.
• Among region, North America segment is expected to account for largest market share in 2021, owing to rising healthcare expenditure by government on anal cancer treatment and diagnosis. For instance, in August 2021, the Icahn School of Medicine, New York received a grant of around US$ 4 million by the National Cancer Institute, U.S. for carrying out a clinical study to determine screening of anal cancer in women who have been diagnosed with HPV (human papillomavirus) infection.
• Key players operating in the global anal cancer market include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited